Key result
Astragaloside IV significantly improved cardiac function, reduced infarct size, and prevented apoptosis in diabetic mice with myocardial infarction by regulating the MAPK signaling pathway.
Why the study?
Type 2 diabetes mellitus increases the risk of cardiovascular disease including MI, with inflammation and apoptosis implicated in its pathophysiology, motivating an evaluation of astragaloside IV on MI in diabetic mice.
Does astragaloside IV improve cardiac function and reduce apoptosis in diabetic myocardial infarction models?
Does astragaloside IV improve cardiac function and reduce apoptosis in diabetic myocardial infarction models?
p-value: p=<0.05
Astragaloside IV shows potential as a cardioprotective agent in diabetic myocardial infarction by reducing apoptosis and restoring cardiac function.
No change to clinical practice in diabetic MI; leaves open translation of MAPK findings to human trials.
BACKGROUND: Type 2 diabetes mellitus increases the risk of cardiovascular disease including myocardial infarction (MI). Inflammation and apoptosis have been implicated in the pathophysiology of MI. In the present study, the effects of astragaloside IV (AS-IV) on MI in diabetic mice were evaluated. METHODS: High glucose/high fat (HG/HF) and hypoxia culture condition were established to mimic diabetic condition. After administration of AS-IV to H9c2 myocytes, the cell apoptosis, viability, and activation of mitogen-activated protein kinase (MAPK) signaling pathways were detected. MI was induced in streptozotocin-induced diabetic mice. After administration of AS-IV to mice, cardiac function, cardiac fibrosis, inflammation, and activation of MAPK signaling pathway were detected. RESULTS: Astragaloside IV treatment significantly inhibited HG/HF and hypoxia-induced apoptosis of H9c2. AS-IV inhibited activation of JNK and p38 signaling pathway while promoting the activation of EKR signaling pathway. AS-IV treatment rescued cardiac function, suppressed cardiac fibrosis and inflammation, and differently regulated the activation of MAPK signaling pathways. CONCLUSION: Astragaloside IV prevented apoptosis and restored cardiac function in MI, which may be due to the regulation of MAPK signaling pathway in diabetes.
No takes yet. Share an insight, caveat, or question.
Sun et al. (2021) studied Myocardial infarction in diabetes. Astragaloside IV vs. PBS was evaluated on Cardiac function (LVEF, LVFS) and apoptosis (p=<0.05). Astragaloside IV significantly improved cardiac function, reduced infarct size, and prevented apoptosis in diabetic mice with myocardial infarction by regulating the MAPK signaling pathway.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: